Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

  1. Langdahl, B.L.
  2. Libanati, C.
  3. Crittenden, D.B.
  4. Bolognese, M.A.
  5. Brown, J.P.
  6. Daizadeh, N.S.
  7. Dokoupilova, E.
  8. Engelke, K.
  9. Finkelstein, J.S.
  10. Genant, H.K.
  11. Goemaere, S.
  12. Hyldstrup, L.
  13. Jodar-Gimeno, E.
  14. Keaveny, T.M.
  15. Kendler, D.
  16. Lakatos, P.
  17. Maddox, J.
  18. Malouf, J.
  19. Massari, F.E.
  20. Molina, J.F.
  21. Ulla, M.R.
  22. Grauer, A.
Aldizkaria:
The Lancet

ISSN: 1474-547X 0140-6736

Argitalpen urtea: 2017

Alea: 390

Zenbakia: 10102

Orrialdeak: 1585-1594

Mota: Artikulua

DOI: 10.1016/S0140-6736(17)31613-6 GOOGLE SCHOLAR